NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model

200691 citationsJournal Article

Authors

James C. Cusack · Massachusetts General Hospital

Rong Liu · Massachusetts General Hospital

Lijun Xia · Massachusetts General Hospital

Ta‐Hsiang Chao · Prometheus Biosciences (United States)

Christine Pien · Prometheus Biosciences (United States)

Wei Niu · Prometheus Biosciences (United States)

Vito J. Palombella

Abstract

The high level of proteasome inhibition achieved by NPI-0052 is well tolerated and significantly improves the tumoricidal response to multidrug treatment in a colon cancer xenograft model. Further evaluation of this novel proteasome inhibitor in clinical trials is indicated.

Topics & Keywords

Ubiquitin and proteasome pathways Cancer-related Molecular Pathways Cell death mechanisms and regulation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 12, Issue 22, pp. 6758-6764

DOI: 10.1158/1078-0432.ccr-06-1151

Field-Weighted Citation Impact: 4.77